Grace Therapeutics files NDA for GTx‑104 after Phase 3 win, $20M cash and $13.7M raise

Grace Therapeutics, Inc. (NASDAQ: ACST) - Q1 (quarter ended June 30, 2025) snapshot

What's happening inside: management has pivoted to focus on the lead asset GTx‑104, completed the Phase 3 STRIVE‑ON program, submitted an NDA for GTx‑104 on June 25, 2025, and raised a material private placement in Feb 2025 to extend runway. The company is smaller and concentrated on hospital commercialization planning for an IV nimodipine product. Key financials reflect lower R&D spend after the Phase 3 completion, continued operating losses, a stronger cash position vs. prior financings, and non‑cash volatility from warrant fair‑value movements.

Key facts & statistics (figures as reported; $ in thousands unless noted)
- Cash and cash equivalents: $20,005 (June 30, 2025) - down from $22,133 at March 31, 2025.
- Cash equivalents (treasury bills): $18,087 measured at Level 1.
- Total assets: $69,805; Total liabilities: $6,255; Total stockholders' equity: $63,550.
- Intangible assets: $41,128; Goodwill: $8,138 (total intangible + goodwill = $49,266).
- Accumulated deficit: $(224,049).
- Trade and other payables: $2,315; CMO/CRO near‑term commitments ≈ $185 for next 12 months.
- Net loss (three months ended June 30, 2025): $3,362 (reported) - loss per share: $0.21; weighted‑average shares: 15,924,522.
- Operating expenses: R&D $955 (Q) vs. $2,708 (prior year Q); G&A $2,135 vs. $2,255 (prior year Q).
- Net cash used in operating activities: $(1,801) vs. $(3,596) in the prior period (improved cash burn).
- 2025 private placement net proceeds: $13,705 (closed Feb 11, 2025).
- Outstanding warrants (as of June 30, 2025): 2023 Common Warrants (liability) 2,536,391; 2025 Common Warrants (equity) 4,418,292; various pre‑funded warrants outstanding.
- Derivative warrant liabilities (fair value): $1,628 (ending balance) - change in fair value for quarter: $(487).
- Black‑Scholes inputs (June 30, 2025): share price $2.97; risk‑free rate 4.22%; expected volatility 66.72%; weighted avg fair value per 2023 warrant $0.64.

Positive points
- Clinical and regulatory progress: Phase 3 STRIVE‑ON met its primary endpoint and the company filed an NDA for GTx‑104 (June 25, 2025). Clinical readouts also reported improved dose intensity and advantageous PK variability vs oral nimodipine.
- Cash raise and runway: $13.7M net private placement in Feb 2025 and $20.0M cash balance provide funding headroom; management states cash sufficient for at least 12 months from filing date.
- Lower near‑term R&D spend: R&D fell sharply (Q down from $2,708 to $955) after pivotal trial completion, reducing near‑term cash burn.
- Improved operating cash flow: net cash used in operations improved to $(1,801) from $(3,596), showing lower burn and better working capital dynamics.

Negative points / risks
- Still loss making: net loss widened vs some expectations - $3,362 this quarter (despite lower R&D) driven by non‑cash warrant fair‑value losses and loss of prior period tax benefit.
- Non‑cash volatility from warrants: change in fair value of derivative warrant liabilities produced a $(487) hit this quarter and is sensitive to share price and volatility - this can swing reported net loss materially quarter-to-quarter.
- No product revenue: the company remains pre‑revenue and depends on FDA acceptance/approval for GTx‑104 to commercialize; further financing may be required if approval/commercial timelines extend.
- Clinical safety signals & outcomes nuance: STRIVE‑ON showed more deaths in the GTx‑104 arm (8 vs 4) though reported as disease‑related and not attributed to drug - such items can complicate regulatory review and market perception.
- Dilution/option overhang: ~1.3M options outstanding and >7M common warrants (total across 2023/2025 instruments) create potential dilution if exercised; some warrants are liability‑classified which also drives P&L volatility.
- Partial valuation allowance for deferred tax assets: management placed a partial valuation allowance, removing a ~$724 tax benefit seen in the prior year quarter.

Operational highlights from the filings
- STRIVE‑ON topline clinical data: 19% reduction in at least one drug‑related clinically significant hypotension event (28% vs 35%); 54% of GTx‑104 patients reached ≥95% relative dose intensity vs 8% on oral; favorable 90‑day modified Rankin trends; pharmacoeconomics and ICU metrics favored GTx‑104.
- GTx‑104 PK: IV formulation achieves ~100% bioavailability vs ~7% for oral capsules in PK bridging studies; delivered to >200 subjects across studies.
- Pipeline prioritization: GTx‑104 prioritized; GTx‑102 and GTx‑101 development is deprioritized pending additional funding or partnerships.

Bottom line - analyst take
Grace Therapeutics has de‑risked a key clinical milestone (Phase 3 & NDA filing) and secured a Feb 2025 financing that extends near‑term runway. Financials show meaningful reduction in R&D spend and improved cash burn, but the company remains pre‑revenue, loss‑making, and exposed to P&L swings from warrant re‑measurement and potential dilution from outstanding warrants/options. FDA review outcomes for the NDA and the company's ability to raise or conserve capital after review will be the decisive next drivers for value realization.

If you want, I can convert these bullets into a concise slide/one‑pager for investors or produce a short market reaction note with modeled runway and dilution scenarios.